News | July 10, 2022
Sirio Pharma announces agreement to acquire best formulations
The combined company will be able to better serve both our global and regional customers with local production
The combined company will be able to better serve both our global and regional customers with local production
Domestic devices are usually preferred over imported medical devices in the national or regional procurement.
Site Enhances New Modality CRDMO Platform Capacity for Customers
Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Guindo will be responsible for leading the development and implementation of the company’s long-term strategy for the Human Health portfolio.
Subscribe To Our Newsletter & Stay Updated
